tiprankstipranks
Trending News
More News >
Northwest Biotherapeutics (NWBO)
:NWBO
Advertisement

Northwest Biotherapeutics (NWBO) Price & Analysis

Compare
505 Followers

NWBO Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.21%0.04%99.76%
0.21%
Insiders
0.04% Other Institutional Investors
99.76% Public Companies and Individual Investors

NWBO FAQ

What was Northwest Biotherapeutics’s price range in the past 12 months?
Northwest Biotherapeutics lowest stock price was $0.17 and its highest was $0.48 in the past 12 months.
    What is Northwest Biotherapeutics’s market cap?
    Northwest Biotherapeutics’s market cap is $388.70M.
      When is Northwest Biotherapeutics’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Northwest Biotherapeutics’s earnings last quarter?
      Currently, no data Available
      Is Northwest Biotherapeutics overvalued?
      According to Wall Street analysts Northwest Biotherapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Northwest Biotherapeutics pay dividends?
        Northwest Biotherapeutics does not currently pay dividends.
        What is Northwest Biotherapeutics’s EPS estimate?
        Northwest Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Northwest Biotherapeutics have?
        Northwest Biotherapeutics has 1,457,994,100 shares outstanding.
          What happened to Northwest Biotherapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Northwest Biotherapeutics?
          Currently, no hedge funds are holding shares in NWBO

          Company Description

          Northwest Biotherapeutics

          Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
          Similar Stocks
          Company
          Price & Change
          Follow
          Altimmune
          Checkpoint Therapeutics
          Phathom Pharmaceuticals
          Tourmaline Bio
          Rapport Therapeutics, Inc.
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis